R
Rebecca Bornheimer
Publications - 5
Citations - 47
Rebecca Bornheimer is an academic researcher. The author has contributed to research in topics: Retrospective cohort study & Spinal cord injury. The author has an hindex of 3, co-authored 5 publications receiving 26 citations.
Papers
More filters
Journal ArticleDOI
Relationship of American Spinal Injury Association Impairment Scale Grade to Post-injury Hospitalization and Costs in Thoracic Spinal Cord Injury.
Ellen Dukes,Steven Kirshblum,Steven Kirshblum,Alex A. Aimetti,Sarah S Qin,Rebecca Bornheimer,Gerry Oster +6 more
TL;DR: People with less severe thoracic SCI, as reflected in AIS grade, spend fewer days in hospital over their lifetimes, leading to lower costs of inpatient care, which may provide cost savings in addition to addressing substantial unmet need.
Journal ArticleDOI
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
Ammar Al-Chalabi,Adriano Chiò,Charlotte Merrill,Gerry Oster,Rebecca Bornheimer,Wendy Agnese,Stephen Apple +6 more
TL;DR: The King’s and MiToS staging systems provided utility in assessing clinical progression in Edaravone Study 19 and may support the use of staging systems as end points in ALS clinical trials and to understand the timing of benefit as measured by these scales.
Journal ArticleDOI
Cost-Effectiveness Of Lenalidomide and Bortezomib In Patients With Previously Untreated Multiple Myeloma (MM)
TL;DR: In patients with previously untreated MM, cost-effectiveness ratios for MPR-R and VMP are well within the range reported for other well-accepted novel therapies in oncology.
Journal ArticleDOI
Change in Healthcare Utilization and costs in Patients with Major Depressive Disorder (MDD) initiating adjunctive Therapy with Second-Generation Antipsychotics (SGAS)
Journal ArticleDOI
Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States.
TL;DR: Most patients with CIC receive linaclotide or lubiprostone for <6 months; few remain on therapy for >1 year; additional research is warranted to understand the potential reason(s) for early discontinuation.